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Manual assisted cognitive behaviour therapy is as effective as
treatment as usual for deliberate self harm, but is more cost
effective
Tyrer P, Thompson S, Schmidt U, et al. Randomized controlled trial of a brief cognitive behaviour
therapy versus treatment as usual in recurrent deliberate self-harm: the POPMACT study. Psychol Med
2003;33:969–76; and Byford S, Knapp M, Greenshields J, et al. Cost-effectiveness of brief cognitive
behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making
approach. Psychol Med 2003;33:977–86.
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Q Is manual assisted cognitive behaviour therapy more effective and more cost effective than treatment as usual in peoplewith recurrent episodes of deliberate self harm?
METHODS
Design: Randomised controlled trial.
Allocation: Concealed.
Blinding: Unblinded.
Follow up period: 12 months.
Setting: Five centres in Glasgow, Edinburgh, Nottingham, West
London, and South London; recruitment May 1998 to April 2000.
Patients: 480 people, aged between 16 and 65 years, presenting
with recurrent (at least 2 episodes) deliberate self harm. Exclusions:
diagnosis of a psychotic or bipolar disorder; needing in-patient
psychiatric treatment; primary diagnosis of substance dependence.
Intervention: Participants were randomised to manual assisted
cognitive behaviour therapy (MACT; 239 people) or treatment as
usual (TAU; 241 people). The MACT group received a booklet
based on cognitive behavioural therapy (CBT) principles and
were offered up to 7 sessions with a MACT trained therapist. The
TAU group was offered the standard treatment available in each
location, including: problem solving approaches (Nottingham);
dynamic psychotherapy (South London); GP or voluntary group
referral (West London and Edinburgh); or short term counselling
(Glasgow). Members of the TAU group already receiving
standard care were offered continuation of this care. Assessment
interviews were carried out at 6 and 12 months. Incidences of self
harm were self reported during a modified Linehan Parasuicide
History Interview and verified using GP notes and A&E records.
Economic data were collected at baseline, 6 and 12 months,
using a modified Client Service Receipt Inventory. Data collected
covered all service providing sectors, productivity losses,
accommodation and living costs.
Outcomes: Efficacy: a repeat self harm episode within the
following year. Cost: cost per patient over 12 months. Cost
effectiveness: incremental cost effectiveness ratio (ICER) over 12
months.
Patient follow up: Efficacy analysis 84%; cost analysis 83%.
MAIN RESULTS
Efficacy: at 12 months, the proportion of participants repeating
deliberate self harm was not significantly different between groups
(AR 39% with MACT v 46% with TAU; OR 0.78, 95% CI 0.53 to 1.14;
analysis not by intention to treat). Cost: MACT was significantly
cheaper than TAU over 6 months, but did not maintain significance
over 12 months (6 month mean difference in cost per patient: –£897,
95% CI –£1747 to –£48; 12 month mean difference in cost per patient:
–£838, 95% CI –£2142 to £466). Cost effectiveness: the ICER was –£120
per 1% reduction in the proportion of participants with a repeat self
harm episode. The likelihood that MACT is more cost effective than
TAU, based on cost effectiveness acceptability curves, is over 90%.
CONCLUSIONS
MACT is as effective as usual treatment in reducing recurrences of
deliberate self harm, however, it is more cost effective.
NOTES
Authors note that there were sociodemographic differences between
participants included and those excluded from the economic analysis
due to missing economic data. There was a centre bias among
excluded participants, and they were younger and had cost less in the
6 months prior to baseline. This may affect generaliseability of
results.
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Commentary
T
hese companion papers by Tyrer et al and Byford et al are excellent
models of psychiatric research which have produced sobering and
disappointing results in terms of effecting a reduction in deliberate
self harm. However, it would be reassuring to health administrators that
there may be a reduction in health care expenditure with the manual
assisted cognitive behaviour therapy.
If such a well designed study cannot demonstrate an improved clinical
outcome, a finding which is consistent with the majority of previous
research, questions arise not only about the wisdom of pursuing further
such studies, but also whether the correct issues are being addressed.
Consider the subjects of the study: they have had a previous episode,
and therefore they would be a more homogeneous group; they did not
require in-patient care, so they may be less ill than some seen in practice;
and they did not have a psychotic disorder or bipolar disorder, or a
primary diagnosis of substance dependence, therefore precluding a
further substantial group seen in practice. And yet they are a patient
group united by deliberate self harm, a behaviour related to many
disparate stressors. Is such a behaviour sufficient to form a cohesive
group worthy of such intensive study?
In 1828 George Burrows1 wrote that ‘‘The medical treatment of the
propensity to suicide, whether prophylactic or therapeutic, differs not
from that which is applicable in cases of ordinary insanity.’’ This advice to
address the underlying condition appears to have been overlooked in our
attempts to demonstrate our ability to influence a behaviour.
It is doubtful whether a better study design focusing on deliberate self
harm could be implemented. Indeed, perhaps the most important
implication from this study is that future psychiatric research should
focus on the antecedents of deliberate self harm, that is those conditions
which are associated with it rather than the behaviour itself.
Robert Goldney MB, BS, MD, FRANZCP, FRC Psych
Professor of Psychiatry, University of Adelaide, Australia
1 Burrows, GM. Commentaries on the causes, forms, symptoms, and
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